What's Happening?
Ardena, a contract development and manufacturing organization (CDMO) and bioanalytical contract research organization (CRO), has opened a new bioanalytical laboratory in Somerset, New Jersey. This state-of-the-art facility is designed to support precision
medicines and complex therapies, enhancing Ardena's scientific capabilities in North America. The laboratory features advanced systems for quantitative analysis, including LC-MS/MS and immunochemistry platforms, and aims to support both preclinical and clinical studies. This expansion is part of Ardena's strategy to strengthen its global bioanalytical network and collaborate more closely with clients in the U.S.
Why It's Important?
The establishment of a new bioanalytical laboratory by Ardena in the U.S. is a strategic move to enhance its service offerings in the growing field of precision medicine. This expansion allows Ardena to provide high-quality bioanalytical services closer to its North American clients, potentially accelerating drug development processes. The facility's capabilities in analyzing complex therapeutic modalities could attract more biopharma companies seeking reliable partners for their clinical trials. This development underscores the increasing demand for specialized bioanalytical services in the pharmaceutical industry.
What's Next?
Ardena plans to further expand its Somerset site by adding more laboratory space and analytical platforms, such as qPCR and flow cytometry. This expansion will be supported by a fully integrated electronic quality management system (eQMS) and laboratory information management system (LIMS) to ensure data integrity and efficient study execution. As the demand for bioanalysis and biomarker services grows, Ardena's continued investment in its U.S. operations positions it to meet the needs of the biopharma industry effectively.
